trending Market Intelligence /marketintelligence/en/news-insights/trending/aVQPLOV6zh5vBZ99oIC3Ew2 content esgSubNav
In This List

Midatech Pharma to raise $3M in registered direct offering


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Midatech Pharma to raise $3M in registered direct offering

Midatech Pharma PLC agreed to sell 3 million American depositary shares to an institutional investor at $1 apiece in a registered direct offering.

The Cardiff, U.K.-based biotechnology company expects to generate $3 million in gross proceeds from the transaction. Each ADS represents 20 ordinary shares of the company.

Additionally, the institutional investor in the offering will receive unregistered warrants to buy up to 3 million ADSs in a concurrent private placement. The warrants are exercisable for $1.25 apiece and will expire in five and a half years.

Closing of the offering will occur on or about Oct. 25, subject to closing conditions.

Midatech applied for the admission of the 60 million new ordinary shares to trading on the London Stock Exchange's AIM, expected to occur Oct. 29.

H.C Wainwright & Co. is acting as the exclusive placement agent in the offering.